Moore DT - Search Results

1

Racial differences in prostate androgen levels in men with clinically localized prostate cancer.

Mohler JL, Gaston KE, Moore DT, Schell MJ, Cohen BL, Weaver C, Petrusz P. Mohler JL, et al. Among authors: moore dt. J Urol. 2004 Jun;171(6 Pt 1):2277-80. doi: 10.1097/01.ju.0000127739.88383.79. J Urol. 2004. PMID: 15126802

2

The life readiness program: a physical rehabilitation program for patients on hemodialysis.

Tawney KW, Tawney PJ, Hladik G, Hogan SL, Falk RJ, Weaver C, Moore DT, Lee MY. Tawney KW, et al. Among authors: moore dt. Am J Kidney Dis. 2000 Sep;36(3):581-91. doi: 10.1053/ajkd.2000.16197. Am J Kidney Dis. 2000. PMID: 10977791 Clinical Trial.

3

Hand-assisted laparoscopic nephrectomy: prospective evaluation of the learning curve.

Gaston KE, Moore DT, Pruthi RS. Gaston KE, et al. Among authors: moore dt. J Urol. 2004 Jan;171(1):63-7. doi: 10.1097/01.ju.0000099400.50350.9b. J Urol. 2004. PMID: 14665845

4

Impact of race, age, income, and residence on prostate cancer knowledge, screening behavior, and health maintenance in siblings of patients with prostate cancer.

Pruthi RS, Tornehl C, Gaston K, Lee K, Moore D, Carson CC, Wallen EM. Pruthi RS, et al. Eur Urol. 2006 Jul;50(1):64-9. doi: 10.1016/j.eururo.2005.09.024. Epub 2005 Dec 12. Eur Urol. 2006. PMID: 16364537

5

Characterization of biochemical recurrence after radical prostatectomy.

Molitierno J, Evans A, Mohler JL, Wallen E, Moore D, Pruthi RS. Molitierno J, et al. Urol Int. 2006;77(2):130-4. doi: 10.1159/000093906. Urol Int. 2006. PMID: 16888417

6

The use of erythropoietin in patients undergoing radical prostatectomy: effects on hematocrit, transfusion rates and quality of life.

Gaston KE, Kouba E, Moore DT, Pruthi RS. Gaston KE, et al. Among authors: moore dt. Urol Int. 2006;77(3):211-5. doi: 10.1159/000094811. Urol Int. 2006. PMID: 17033207 Clinical Trial.

7

Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.

Titus MA, Zeithaml B, Kantor B, Li X, Haack K, Moore DT, Wilson EM, Mohler JL, Kafri T. Titus MA, et al. Among authors: moore dt. PLoS One. 2012;7(1):e30192. doi: 10.1371/journal.pone.0030192. Epub 2012 Jan 17. PLoS One. 2012. PMID: 22272301 Free PMC article.

8

A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.

Pruthi RS, Derksen JE, Moore D. Pruthi RS, et al. BJU Int. 2004 Feb;93(3):275-8. doi: 10.1111/j.1464-410x.2004.04601.x. BJU Int. 2004. PMID: 14764122 Clinical Trial.

9

Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.

Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C, Wallen E. Pruthi RS, et al. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2172-7. doi: 10.1158/1078-0432.CCR-05-2067. Clin Cancer Res. 2006. PMID: 16609031 Clinical Trial.

10

A prospective evaluation of the short-term impact and recovery of health-related quality of life in men undergoing radical prostatectomy.

Kouba E, Hubbard JS, Moore D, Wallen EM, Pruthi RS. Kouba E, et al. BJU Int. 2007 Jan;99(1):72-6. doi: 10.1111/j.1464-410X.2007.06533.x. BJU Int. 2007. PMID: 17227494

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

253 results

Search Page

Filters